Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
20°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals, Inc. - Common Stock
(NQ:
TARS
)
48.09
+1.62 (+3.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tarsus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
Next >
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
March 12, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
March 12, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Upcoming Investor Conference
March 06, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
April 15, 2024
Via
Investor Brand Network
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
February 20, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
January 30, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
January 13, 2025
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
November 13, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
November 13, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
November 06, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
November 05, 2024
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company’s newly created Medical Organization
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 17, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
September 25, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
August 28, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
May 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Public Offering
March 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
February 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 27, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 20, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 31, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
January 29, 2024
Via
Investor Brand Network
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.